Contemporary data in myeloproliferative neoplasm-unclassifiable: mutational landscape and management of the ‘unclassifiable’

When considering management of MPN-U, for patients in the cellular phase, we consider cytoreduction in patients identified as high-risk, for fibrotic-phase disease, we consider JAK inhibition for splenomegaly/constitutional symptoms and allogeneic transplantation for higher-risk patients, and for accelerated/blast-phase disease we employ hypomethylating-agent based approaches with the intent of allogeneic transplant for eligible patients.